Analyzing the Phase 2a Open Label Study of an Angiotensin II Type 2 Receptor Agonists Improving Lung Function
Time: 12:30 pm
day: Day Two
Details:
- Highlighting the scientific rationale behind targeting angiotensin II type 2 receptor and how ATRAGs promotes alveolar repair
- Exploring an observed improvement in lung function highlighting the potential to halt disease progression, restore lung function and improve outcomes
